Theravance Biopharma, Inc. (TBPH)
17.06
0.00 (0.00%)
USD |
NASDAQ |
Sep 03, 16:00
17.06
0.00 (0.00%)
After-Hours: 20:00
Theravance Biopharma Research and Development Expense (TTM) : 24.46M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 24.46M |
| March 31, 2026 | 30.20M |
| December 31, 2025 | 35.79M |
| September 30, 2025 | 37.97M |
| June 30, 2025 | 39.10M |
| March 31, 2025 | 38.54M |
| December 31, 2024 | 36.04M |
| September 30, 2024 | 34.92M |
| June 30, 2024 | 33.96M |
| March 31, 2024 | 33.31M |
| December 31, 2023 | 38.72M |
| September 30, 2023 | 46.05M |
| June 30, 2023 | 47.38M |
| March 31, 2023 | 52.46M |
| December 31, 2022 | 60.79M |
| September 30, 2022 | 76.66M |
| June 30, 2022 | 109.57M |
| March 31, 2022 | 145.32M |
| December 31, 2021 | 190.64M |
| September 30, 2021 | 224.58M |
| June 30, 2021 | 249.84M |
| March 31, 2021 | 262.54M |
| December 31, 2020 | 260.95M |
| September 30, 2020 | 261.05M |
| June 30, 2020 | 243.87M |
| Date | Value |
|---|---|
| March 31, 2020 | 227.87M |
| December 31, 2019 | 215.67M |
| September 30, 2019 | 202.68M |
| June 30, 2019 | 205.18M |
| March 31, 2019 | 207.40M |
| December 31, 2018 | 201.35M |
| September 30, 2018 | 200.13M |
| June 30, 2018 | 186.78M |
| March 31, 2018 | 181.09M |
| December 31, 2017 | 173.89M |
| September 30, 2017 | 164.85M |
| June 30, 2017 | 157.46M |
| March 31, 2017 | 146.60M |
| December 31, 2016 | 141.71M |
| September 30, 2016 | 132.10M |
| June 30, 2016 | 130.52M |
| March 31, 2016 | 128.82M |
| December 31, 2015 | 129.17M |
| September 30, 2015 | 138.96M |
| June 30, 2015 | 146.91M |
| March 31, 2015 | 162.13M |
| December 31, 2014 | 167.84M |
| September 30, 2014 | 158.11M |
| June 30, 2014 | 152.09M |
| March 31, 2014 | 136.89M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Zymeworks, Inc. | 128.70M |
| Viatris, Inc. | 995.00M |
| Ocular Therapeutix, Inc. | 223.51M |
| ANI Pharmaceuticals, Inc. | 49.91M |
| Corcept Therapeutics, Inc. | 253.86M |